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Dual HIV risk and vulnerabilities among women
who use or inject drugs: no single prevention
strategy is the answer
Nabila El-Bassel a, Wendee M. Wechsberg b, and Stacey A. Shaw a

Purpose of review
This article examines the dual HIV and sexually transmitted infection (STI) risk behaviors engaged in by
women who use or inject drugs; the individual, social, and structural drivers of HIV and STI risk; prevention
strategies; and the implications for multilevel, combined, sex-specific HIV prevention strategies.
Recent findings
Women who use or inject drugs, especially female sex workers, are at dual risk for HIV, the hepatitic C
virus (HCV), and other STIs. In countries with HIV prevalence higher than 20% among injecting drug users
(IDUs), female IDUs have slightly higher HIV prevalence than male IDUs. Women who use or inject drugs
face multilevel drivers that increase their vulnerabilities to HIV, HCV, and STIs. Despite advances in
behavioral HIV prevention strategies for this population, most prevention studies have not sufficiently
targeted dyadic, social, and structural levels. Few recent advances in biomedical HIV prevention have
focused on women who use drugs and their unique needs.
Summary
HIV prevention strategies and services need to address the unique and multilevel drivers that increase the
vulnerabilities to HIV, HCV, and STIs among women who use drugs including those who engage in sex
work. Scaling-up and improving access to multilevel and combined HIV prevention strategies for these
women is central to combating the HIV epidemic.
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INTRODUCTION
Globally, HIV infection among women is escalating,
especially among injection drug users (IDUs) in
Eastern Europe, East Asia, and Central Asia
[1,2,3 ,4,5 ]. This trend is also apparent in other
regions, even among women who use but do not
inject drugs [6 ]. The literature has documented a
fairly recent emergence of noninjection drug use
among women in several African countries [7 ]. Sex
disparities are noticeable, in that female IDUs are
often at greater risk for HIV compared with male
IDUs. A recent systematic review and analysis of
117 studies of drug users across 14 countries with
an HIV prevalence of 20% or greater among drug
users found a slightly higher HIV prevalence among
female IDUs compared with their male counterparts
(odds ratio ¼ 1.18, 95% confidence interval 1.10–
1.26) [8]. Studies have also highlighted the increased
prevalence of the hepatitis C virus (HCV) among
&

&

&
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female IDUs including female sex workers (FSWs)
[9–11].
Women who use drugs and those who engage in
sex trading face individual, social, and structural
drivers that increase their vulnerability to HIV
and sexually transmitted infections (STIs) [3 ]. The
overlap between the IDU and FSW populations is
considerable [6 ,7 ]. Globally, approximately onethird of women who inject drugs turn to sex trading,
which puts them at higher risk for both acquiring
&

&
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KEY POINTS
 Multilevel drivers including individual, social, and
structural level factors influence vulnerability to HIV and
STI risk among women who use or inject drugs.
 The unique contexts and multilevel drivers that influence
women who use or inject drugs, including sex workers,
must be addressed in HIV prevention efforts among
this population.

and use contaminated rinse water than women who
did not share. In a study conducted with 198 HIVseropositive women, mostly crack cocaine users
(80%) from three US cities, having a primary and
casual sex partner more than doubled the risk of
having an STI [28]. In another study, which compared South African adolescent female methamphetamine users (n ¼ 261) with nonusers
(n ¼ 188), Wechsberg et al. [7 ] found that young
female methamphetamine users were six times
more likely not to use condoms compared with
young women who used other drugs and were more
likely to be sexually abused than nonmethamphetamine users. Female IDUs in St Petersburg, Russia,
experienced multiple HIV risks from sharing needles, partner’s drug use, and sexual risk with their
main partners and sex trading partners [5 ].
&

 Additional research is needed on dyadic, social, and
structural level HIV prevention strategies and
biomedical prevention among women who use or
inject drugs.

&&

and transmitting HIV and STIs [12–14,15 ,16].
FSWs and their clients are population bridges for
transmitting HIV to other partners [17].
This article examines studies published within
the past 18 months (2010–2011) that were conducted with women who use or inject drugs including FSWs. This review concentrates on four major
research areas: drug and sexual risk behaviors of
women who use or inject drugs; multilevel drivers
(individual, social, and structural) of HIV and STI
risk; HIV prevention strategies; and implications for
multilevel HIV prevention strategies needed to contain the HIV epidemic among women who use or
inject drugs. This review is timely given the calls for
action to move beyond individual behavioral prevention approaches to multilevel and combined
strategies (behavioral and biomedical) for women
who use or inject drugs.

&

MULTILEVEL DRIVERS
The literature underscores that these intersecting
HIV risks are influenced by multilevel drivers (individual, social, and structural) that affect women’s
vulnerabilities. These drivers operate dynamically
and can shape behaviors within social contexts that
are unique for women who use drugs [29 ].
&&

Individual drivers
Among individual drivers, studies have identified
mental illness as a leading risk factor for HIV [30],
including depression [31], psychiatric disorders
[32–35], personality disorders [36], posttraumatic
stress disorder (PTSD) [37], and complex trauma
[25 ,38]. These mental health conditions may be a
consequence of traumatic events, such as childhood
sexual abuse [39,40], intimate partner violence
(IPV), stigma, discrimination, poverty [3 ,4,41],
exposure to community violence [4,41], and living
a drug culture lifestyle [7 ,25 ,26,42].
&

DUAL RISKS AMONG WOMEN WHO USE
OR INJECT DRUGS AND AMONG FEMALE
SEX WORKERS

&

A number of recent studies have described dual HIV
risks (drugs and sex) among women who use or
inject drugs and among FSWs, including sharing
contaminated needles and syringes [18], using crack
cocaine, and using methamphetamines [19–21].
Risky sex behaviors include unprotected vaginal
and anal sex [21–23] with regular or casual partners
and sex-trading clients [14,24], sexual concurrency
[19,20], and experiencing sexual abuse or rape
by intimate partners and sex-trading clients [25 ,
26,27 ].
In a study of the association between the practice of ‘flashblood’ (whereby an IDU injects herself
with blood extracted from another IDU who
recently injected) and HIV status among 169 female
IDUs from Tanzania, McCurdy et al. [18] found that
flashblood sharers were more likely to inject heroin
&

&

&

&

Social drivers
Social and cultural drivers operate within the social
networks and family and dyadic relationships, in
which values, social norms, and attitudes are engendered, put into practice, and influence HIV risk [9].
Women who use or inject drugs are often stigmatized within their social network because their
behavior contrasts with sex role norms and, as a
result, they have low social status and are often
considered sexually promiscuous or ‘damaged
goods’. Consequently, women are frequently victimized and seen as deserving of abuse [25 ,27 ].
In social dyadic contexts, women who use or
inject drugs often rely on their partners to procure
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the drugs that they share, and women are often
injected by their partners as second users when
sharing drug equipment. Refusing to share needles
and syringes can increase the risk of physical and
sexual IPV, thus heightening the risk for HIV transmission [43]. Refusal to share needles could also
result in loss of the woman’s source of subsistence
and income, and put pressure on her to engage in
high-risk behavior [43]. The likelihood of engaging
in risky behaviors increases as abuse and dependency on drugs increases [44]. FSWs who use drugs
may be more likely to acquiesce to a client’s
demands for unprotected sex if they are under the
influence of drugs or experiencing withdrawal [4].

FSWs, bringing attention to the need for structural
interventions for youth, including sex-specific
housing. A study by Epperson et al. [51] with 415
women receiving methadone treatment found that
arrest and incarceration were significantly associated with a number of sex-risk behaviors, such as
unprotected sex, having multiple sex partners, and
sex with high-risk partners.
Each of these drivers has been found consistently in previous research to be a major impediment
to risk reduction. Women who use drugs often have
limited access to drug abuse treatment, MTPs, SEPs,
voluntary counseling and testing (VCT), antiretroviral therapy (ART), and other HIV-related services,
especially in low-resource settings and countries
where drug use propels the epidemic [3 ]. In
addition, women who use drugs often avoid contact
with the healthcare system, forgoing antenatal care,
which reduces the opportunities to address critical
health needs, including enrollment in ART to
prevent mother-to-child HIV transmission [52].
Compounding the problem, drug abuse treatment
and harm-reduction programs tend to be characterized by a lack of integrated care [53,54], and few
programs are equipped to adequately address
women’s needs and vulnerabilities, such as IPV,
pregnancy, and childcare [3 ,52,55].
&

Structural drivers
Although there has been a call for attention to ‘risk
environments’ as a driver [4,29 ,45], only a handful
of recently published studies have addressed this
domain. Risk environments comprise structural factors exogenous to the individual that directly or
indirectly act as barriers to, as well as facilitators
of, individual HIV risk and prevention behaviors [4].
These factors include laws, policies, incarceration,
criminalization of drug use, economic conditions,
poverty, sex inequality, sex-based violence, human
rights violations [27 ,29 ,46], and barriers to accessing HIV care, services, and drug abuse treatment
[47–49].
A study by Chakrapani et al. [45] examined the
risk behaviors and the structural contexts of risk
among female and male IDUs in northern India,
where injecting drug use is the major route of HIV
transmission, and found that a number of structural
contexts are associated with individual HIV risks.
These included barriers to carrying needles and
syringes because of fear of harassment by police
and antidrug-use organizations, lack of sterile
needles and syringes in drug-dealing locales, limited
access to needles and syringes sold at pharmacies,
inadequate coverage by needle and syringe exchange
programs (SEPs), no availability of sterile needles in
prisons, and withdrawal symptoms superseding concerns about health.
A study by Strathdee et al. [15 ] among FSW
IDUs in northern Mexico found that FSW IDUs who
were HIV positive were more likely to have syphilis,
often or always inject drugs with clients, and experience confiscation of syringes by police when compared to other IDU FSWs who were HIV negative.
Miller et al. [50] examined structural vulnerabilities
among FSWs in Vancouver, Canada, and found that
younger FSWs (24 years old) were more likely to be
homeless, work in public spaces, and not access
methadone treatment programs (MTPs) than older
&&
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MULTILEVEL HIV PREVENTION
HIV prevention and treatment strategies for women
who use drugs include individual, group, structural,
and biomedical approaches.

Individual-focused behavioral prevention
Individual-focused behavioral prevention approaches have included a number of core components
such as skills building; negotiation of safer sex practices; promotion of condom use; serostatus knowledge and HIV testing; safety planning to deal
with IPV; mental health; empowerment skills to
help women access care, services, and employment [28,46,56–60]; and reducing PTSD symptoms
[30,38]. Typically, these components are delivered in
an individual or group modality and they were found
to assist women in reducing sex and drug risks.
However, the responsibility is principally placed on
the woman to make changes in her social contexts
and to convince her partner to engage in safer sex
practices.

Social prevention
Although social level prevention strategies (e.g.,
couple-based, family, social network, communitybased) for women who use drugs have been
Volume 7  Number 4  July 2012
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promoted, this review found that these approaches
were rarely designed and tested in the recent literature. One social level HIV prevention strategy
documented is a couple-based approach. Project
Renaissance is an HIV prevention intervention for
IDUs which was conducted in Kazakhstan [61]. This
trial demonstrated the feasibility and preliminary
effects of a dyadic HIV intervention in reducing
sex-related and drug-related HIV risk. Couples who
inject drugs, who participated together in four HIV
skills building sessions, were significantly more likely
to increase condom use and decrease unsafe injection
acts at the 3-month follow-up than couples who
received four health promotion sessions. A recent
US study with 282 HIV-negative drug-using couples
(564 individuals) found that at 12-month follow-up,
there was a 41% reduction in the incidence rate of the
number of unprotected sex acts with the intimate
partner and a 39% reduction in the unprotected sex
acts with other sex partners when the couple received
the intervention together (seven sessions) compared
with when one person received the same sessions
alone [62 ]. Bringing couples together sends a
message that the responsibility for HIV risk reduction
rests with both partners and underscores that each
partner may place the other at risk.
&

Structural prevention
Structural HIV prevention aimed at changing the
social conditions and policies that affect the ability
of women to protect themselves from HIV infection also remain limited in the literature that we
reviewed. One study focused on microfinance
strategies among FSWs in India, finding that
participation in this economic intervention led to
a higher income at 6-month follow-up, lower
monthly earnings from sex work, and fewer sex
partners and sex-exchange partners than the control
group [63].

Biomedical prevention
The HIV field has witnessed striking biomedical
advances – such as in the recent Center for the AIDS
Programme of Research in South Africa trial, in
which 1% tenofovir gel reduced HIV transmission
by 39% and genital herpes by 51% [64]. In the HIV
Prevention Trials Network (HPTN) 052 study, early
initiation of ART reduced the transmission of HIV
by 96% [65]. In the Partner’s PreP study, daily tenofovir (TDF and TDF/FTC) reduced HIV transmission
among serodiscordant couples by 62% among men
and 73% among women [66]. Despite advances in
biomedical HIV prevention strategies and ongoing
research efforts [67], the number of women who use

or inject drugs in these studies remains limited or
unknown. Moreover, in this biomedical research,
questions remain unanswered about the barriers to
recruitment and adherence, as well as the engagement of women who use or inject drugs and FSWs.
Although the recent findings on the efficacy of
microbicides have been mixed [68], women who
use drugs and who engage in sex work are not fully
included in this research.
The findings from modeling research demonstrate the significance of combination HIV prevention strategies (MTP, SEP, VCT, and ART) for IDUs at
the population level in altering the course of the
HIV epidemic [69]. Strathdee et al. [70] showed that
in countries where HIV epidemics among IDUs are
established or emerging, the benefits of these combination interventions were increased by structural
interventions that optimized either access to or
efficacy of these intervention components. This
situation underscores the increased need to deliver
effective prevention for women that includes both
biomedical and multilevel behavioral prevention
strategies.

CONCLUSION
Research stresses that understanding the local
epidemic is the starting point for effective HIV
prevention for women who use drugs. Addressing
dual risks and providing combination, multilevel
HIV prevention strategies are crucial to stop the
epidemic [8]. This review of recent literature has
shown progress in behavioral HIV prevention
strategies targeting the individual, with a strong
emphasis on women’s unique needs, addressing
IPV, relationship contexts, mental health, and
improving skills to assist access to HIV care and
treatment. For social prevention level approaches,
this literature has produced limited evidence-based
HIV prevention strategies targeting the community,
social network, family, and service settings. Recent
research describes some progress in couple-based
HIV prevention for female drug users, but this
modality also remains scarce [62 ]. Structural level
prevention addressing poverty, laws, and policies
affecting the lives of women who use drugs also
remains limited.
The literature underscores the need for public
policies to fight discrimination and sex-based
violence; to stop police mistreatment, arrest, and
registration of female drug users; and to increase the
access to HIV treatment and care. It also calls for
increased funding to make drug abuse treatment
and HIV services more available and friendlier to
women by addressing sex-specific needs such as
antenatal care, childcare, and prevention of IPV
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and trauma; and by protecting the human rights of
women who use drugs [3 ]. The literature acknowledges the need for a combination of behavioral and
biomedical prevention strategies (e.g., SEPs, MTPs,
ART, PreP, and microbicides) to optimize the HIV
prevention impact. Overall, the research underscores that no single prevention strategy is sufficient
to reduce HIV risk and that a multilevel prevention approach combining individual, social, structural, and biomedical prevention may be most
efficacious.
Implementation and scale-up of evidence-based
HIV prevention for women who use drugs must
consider the unique social contexts and multilevel
drivers of risk to ensure successful outcomes and
sustainability of HIV-risk reduction efforts. Women
vulnerable to HIV often do not have the political
capital to ensure multitier changes to enhance their
economic power. Until there is greater equality in
global regions where women are at most risk for
HIV, targeted and comprehensive combination prevention programs will need to address these disparities.
&
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